Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and Thalidomide

• Status: Completed
• Trial end date: 2005-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this research is to study how helpful the combination of thalidomide and Pamidronate is in controlling multiple myeloma and to study any side effects that may be experienced.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Arkansas
• Treatments: Diphosphonates; Pamidronate; Thalidomide

Criteria

Inclusion Criteria:

• Patients must have a diagnosis of Multiple myeloma with poor hematopoietic reserve (platelet count <100,000 OR inability to collect adequate PBSC to support autologous transplant (4X106 CD34+cells/kg OR WBC <2,000)

• Patients must not be eligible for UARK 98-035

• Patients must be at least 6 weeks beyond previous chemotherapy

• All patients must be informed of the investigational nature of this study and must sign a written informed consent in accordance with UAMS Human Research Advisory Committee and federal guidelines

Exclusion Criteria:

• Prior bisphosphonate therapy within 30 days prior to study entry

• Serum creatinine > 5 mg/dl, ascites, or serum direct bilirubin > 2.5 mg/dl

• Prior plicamycin or calcitonin within 2 weeks of study entry

• Severe cardiac disease, unstable thyroid disease, or epilepsy